Search
AZD2315
go.drugbank.com/drugs/DB06540ExperimentalThe drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase
Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATEZimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnAdditionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.
NCX 950
go.drugbank.com/drugs/DB05849ExperimentalNCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
Dexamethasone acetate
go.drugbank.com/drugs/DB14649ApprovedInvestigationalVet approvedone-fifth and one-third in patients on oxygen therapy and mechanical ventilation, respectively. … [T797,L10695,L14348] Developed in 1957, dexamethasone is structurally similar to other corticosteroids such as [hydrocortisone] and [prednisolone].
Mixtures: BAYCUTEN® N CREMA, BAYCUTEN® N CREMAGLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]
Enalkiren
go.drugbank.com/drugs/DB03395ExperimentalCategories: Agents Acting on the Renin-Angiotensin SystemDihydromorphine
go.drugbank.com/drugs/DB01565ExperimentalIllicitA semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Tienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnIt was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982) … Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.
Oregovomab
go.drugbank.com/drugs/DB04964InvestigationalOregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.